Search

Your search keyword '"Oliva-Hemker, Maria"' showing total 52 results
Start Over Author "Oliva-Hemker, Maria" Publisher elsevier b.v.
52 results on '"Oliva-Hemker, Maria"'

1. Malnutrition increases the risk of 30-day complications after surgery in pediatric patients with Crohn disease.

Author

Ladd, Mitchell R., Garcia, Alejandro V., Leeds, Ira L., Haney, Courtney, Oliva-Hemker, Maria M., Alaish, Samuel, Boss, Emily, and Rhee, Daniel S.

Abstract

Abstract Background Pediatric patients with Crohn disease (CD) are frequently malnourished, yet how this affects surgical outcomes has not been evaluated. This study aims to determine the effects of malnourishment in children with CD on 30-day outcomes after surgery. Study design The ACS NSQIP-Pediatric database from 2012 to 2015 was used to select children aged 5–18 with CD who underwent bowel surgery. BMI-for-age Z-scores were calculated based on CDC growth charts and 2015 guidelines of pediatric malnutrition were applied to categorize severity of malnutrition into none, mild, moderate, or severe. Malnutrition's effects on 30-day complications. Propensity weighted multivariable regression was used to determine the effect of malnutrition on complications were evaluated. Results 516 patients were included: 349 (67.6%) without malnutrition, 97 (18.8%) with mild, 49 (9.5%) with moderate, and 21 (4.1%) with severe malnutrition. There were no differences in demographics, ASA class, or elective/urgent case type. Overall complication rate was 13.6% with malnutrition correlating to higher rates: none 9.7%, mild 18.6%, moderate 20.4%, and severe 28.6% (p < 0.01). In propensity-matched, multivariable analysis, malnutrition corresponded with increased odds of complications in mild and severely malnourished patients (mild OR = 2.1 [p = 0.04], severe OR 3.26 [p = 0.03]). Conclusion Worsening degrees of malnutrition directly correlate with increasing risk of 30-day complications in children with CD undergoing major bowel surgery. These findings support BMI for-age z scores as an important screening tool for preoperatively identifying pediatric CD patients at increased risk for postoperative complications. Moreover, these scores can guide nutritional optimization efforts prior to elective surgery. Level of Evidence IV. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

2. Biologics Delay Progression of Crohn’s Disease, but Not Early Surgery, in Children.

Author

Kerur, Basavaraj, Machan, Jason T., Shapiro, Jason M., Cerezo, Carolina S., Markowitz, James, Mack, David R., Griffiths, Anne M., Otley, Anthony R., Pfefferkorn, Marian D., Rosh, Joel R., Keljo, David J., Boyle, Brendan, Oliva-Hemker, Maria, Kay, Marsha H., Saeed, Shehzad A., Grossman, Andrew B., Sudel, Boris, Kappelman, Michael D., Schaefer, Marc, and Tomer, Gitit

Abstract

Background & Aims Up to 30% of patients with Crohn's disease (CD) require surgery within the first 5 years from diagnosis. We investigated the recent risk of bowel surgery in an inception cohort of pediatric patients with CD and whether early use of biologics (tumor necrosis factor antagonists) alters later disease course. Methods We collected data from the Pediatric Inflammatory Bowel Disease Collaborative Research Group registry on 1442 children (age, ≤16 y) diagnosed with CD from January 2002 through December 2014. Data were collected at diagnosis, 30 days following diagnosis, and then quarterly and during hospitalizations for up to 12 years. Our primary aim was to determine the 10-year risk for surgery in children with CD. Our secondary aim was to determine whether early use of biologics (<3 mo of diagnosis) affected risk of disease progression. Results The 10-year risk of first bowel surgery was 26%. The 5-year risk of bowel surgery did not change from 2002 through 2014, and remained between 13% and 14%. Most surgeries occurred within 3 years from diagnosis. The only predictor of surgery was disease behavior at diagnosis. CD with inflammatory behavior had the lowest risk of surgery compared to stricturing disease, penetrating disease, or both. We associated slowing of disease progression to stricturing or penetrating disease (but not surgery) with early use of biologics, but this effect only became evident after 5 years of disease. Our results indicate that biologics slow disease progression over time (hazard ratio, 0.85; 95% CI, 0.76–0.95). Conclusions In an analysis of data from a registry of pediatric patients with CD, we found that among those with significant and progressing disease at or shortly after presentation, early surgery is difficult to prevent, even with early use of biologics. Early use of biologics (<3 mo of diagnosis) can delay later disease progression to stricturing and/or penetrating disease, but this affect could become evident only years after initial management decisions are made. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

5. Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn’s Disease.

Author

Grossi, Victoria, Lerer, Trudy, Griffiths, Anne, LeLeiko, Neal, Cabrera, Jose, Otley, Anthony, Rick, James, Mack, David, Bousvaros, Athos, Rosh, Joel, Grossman, Andrew, Saeed, Shehzaad, Kay, Marsha, Boyle, Brendan, Oliva-Hemker, Maria, Keljo, David, Pfefferkorn, Marian, Faubion, William, Kappelman, Michael D., and Sudel, Boris

Abstract

Background & Aims It is important to determine the effects of immunomodulators on the ability of children to remain on infliximab therapy for Crohn’s disease (durability of therapy), given the potential benefits and risks of concomitant therapy—especially with thiopurines in male patients. We investigated how immunomodulatory treatment affects the durability of infliximab therapy. Methods We collected data from the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry, from January 2002 through August 2014, on 502 children with Crohn’s disease who participated in a prospective multicenter study. Data were collected from patients who received at least a 3-dose induction regimen of infliximab, and their concomitant use of immunomodulators: no thiopurine or methotrexate treatment, treatment for 6 months or less during infliximab therapy, or treatment for more than 6 months during infliximab therapy. Results The probabilities (± standard error) that children remained on infliximab therapy for 1 year, 3 years, and 5 years after the treatment began were 0.84 ± 0.02, 0.69 ± 0.03, and 0.60 ± 0.03, respectively. Age, sex, and disease extent or location did not affect the durability of infliximab therapy. Greater length of concomitant use of immunomodulators was associated with increased time of infliximab therapy. The probability that patients with more than 6 months of immunomodulator use remained on infliximab therapy for 5 years was 0.70 ± 0.04, compared with 0.48 ± 0.08 for patients who did not receive immunomodulators and 0.55 ± 0.06 for patients who received immunomodulators for 6 months or less ( P < .001). In boys who received immunomodulators for 6 months or more after starting infliximab, the overall durability of infliximab therapy was greater among patients receiving methotrexate than thiopurine ( P < .01); the probabilities that they remained on infliximab therapy for 5 years were 0.97 ± 0.03 vs 0.58 ± 0.08, respectively. Conclusions In children with Crohn’s disease, concomitant treatment with an immunomodulator for more than 6 months after starting infliximab therapy increases the chances that patients will remain on infliximab. In boys, methotrexate appears to increase the durability of infliximab therapy compared with thiopurine. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

6. Medical Malpractice in Gastroenterology.

Author

Conklin, Laurie S., Bernstein, Catherine, Bartholomew, Lori, and Oliva–Hemker, Maria

Subjects
GASTROENTEROLOGY, INTERNAL medicine, DIGESTIVE system diseases, ANESTHESIA in gastroenterology
Abstract

Background & Aims: Gastroenterologists commonly perceive themselves to be at increased legal risk because they perform invasive procedures. However, there is little published information about gastroenterology (GI) malpractice claims. The goal of this study was to evaluate available malpractice claim data within GI. Methods: This study was a database analysis of GI claims submitted by insurance companies to the Physician Insurers Association of America Data Sharing Project from January 1, 1985, to December 31, 2005. Another analysis from 2005 compared GI claims with other subspecialties. Results: Sixty-six percent of physicians involved in claims had previous claims experience. The most common reasons for claims were errors in diagnosis (28%) and improper performance of a procedure (25%). Seventy-two percent of reported closed claims were settled out of court. Of 12,367 total claims in 2005, only 233 (1.8%) were within GI. GI ranked below other procedurally based subspecialties in numbers of claims per physician. Conclusions: GI does not rank highly among subspecialties in malpractice claims and only a minority of claims are procedure-related. Physicians with claims experience are likely to have further claims against them and should consider evaluating their practices. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

7. Corticosteroid Therapy in the Age of Infliximab: Acute and 1-Year Outcomes in Newly Diagnosed Children With Crohn’s Disease.

Author

Markowitz, James, Hyams, Jeffrey, Mack, David, LeLeiko, Neal, Evans, Jonathan, Kugathasan, Subra, Pfefferkorn, Marian, Mezoff, Adam, Rosh, Joel, Tolia, Vasundhara, Otley, Anthony, Griffiths, Anne, Moyer, M. Susan, Oliva–Hemker, Maria, Wyllie, Robert, Rothbaum, Robert, Bousvaros, Athos, Del Rosario, J. Fernando, Hale, Sandra, and Lerer, Trudy

Subjects
CORTICOSTEROIDS, THERAPEUTICS, INFECTIOUS disease transmission, PATIENTS
Abstract

Background & Aims: The aim of this study was to describe 3-month and 1-year outcomes of children with Crohn’s disease (CD) treated with corticosteroids within 30 days of diagnosis, with particular emphasis on the influence of infliximab on these outcomes. We also aimed to determine whether there are clinical or laboratory characteristics associated with corticosteroid therapy outcomes. Methods: Data from 109 children were drawn from a multicenter observational registry that was started in 2002. Clinical characteristics and data on corticosteroid and other therapies were recorded prospectively. Corticosteroid therapy outcomes at 3 months were defined as complete acute response, partial response, or corticosteroid resistance. At 1 year, corticosteroid responsiveness, dependence, and surgical rates were determined. Infliximab’s influence on short- and long-term outcomes also was investigated. Results: At 3 months, 65 of 109 (60%) patients had a complete acute response to corticosteroids, 26 (24%) had a partial response, and 18 (17%) were corticosteroid resistant. At 1 year, 61% were corticosteroid responsive, 31% were corticosteroid dependent, and 8% required surgery. Irrespective of the duration of corticosteroid treatment, 16 of 24 of corticosteroid-dependent/resistant patients rapidly discontinued corticosteroids after starting infliximab. No clinical or laboratory characteristics at diagnosis predicted short-term outcome. Growth impairment at diagnosis increased risk for corticosteroid dependence or surgery at 1 year. Conclusions: At 3 months, 84% of children had a complete or partial response to corticosteroids. However, despite concomitant immunomodulators, at 1 year 31% were corticosteroid dependent and 8% required surgery. Infliximab improves outcomes of corticosteroid-dependent/resistant patients because the duration of corticosteroid use can be controlled by initiating treatment with infliximab. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

8. The Natural History of Corticosteroid Therapy for Ulcerative Colitis in Children.

Author

Hyams, Jeffrey, Markowitz, James, Lerer, Trudy, Griffiths, Anne, Mack, David, Bousvaros, Athos, Otley, Anthony, Evans, Jonathan, Pfefferkorn, Mariann, Rosh, Joel, Rothbaum, Robert, Kugathasan, Subra, Mezoff, Adam, Wyllie, Robert, Tolia, Vasundhara, delRosario, J. Fernando, Moyer, M. Susan, Oliva–Hemker, Maria, and LeLeiko, Neal

Subjects
CORTICOSTEROIDS, THERAPEUTICS, INFLAMMATORY bowel diseases, INTESTINAL diseases
Abstract

Background & Aims: The aim of this study was to determine the clinical outcome after corticosteroid therapy in children who are newly diagnosed with ulcerative colitis (UC). Methods: Data were gathered prospectively from the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry database between January 2002 and March 2005. All children who were newly diagnosed with inflammatory bowel disease younger than the age of 16 years were managed according to the dictates of their respective physicians. Demographic, clinical, and laboratory data were collected at diagnosis, at 30 days, and then quarterly. Patients were classified as corticosteroid responsive, corticosteroid dependent, or refractory, and outcomes were determined at 3 months and at 1 year. Results: Ninety-seven patients had a diagnosis of UC and a minimum of 1 year of follow-up evaluation; 77 (79%) received corticosteroids (62 within 30 days of diagnosis [early] and 15 between 31 days and 6 months [late]). At diagnosis, 81% of corticosteroid-treated patients (age, 11.3 ± 3.5 y) had moderate/severe disease, and 81% had pancolitis. For those treated early with corticosteroids, disease activity at 3 months was inactive in 60%, mild in 27%, and moderate/severe in 11%. At 1 year, 31 of 62 (50%) of the early corticosteroid-treated patients were considered corticosteroid responsive and 28 (45%) were corticosteroid dependent. A total of 4 patients receiving corticosteroids (5%) required colectomy in the first year. Immunomodulators were used in 61% of all corticosteroid-treated patients. Conclusions: Although short-term clinical response to corticosteroids in children with newly diagnosed UC is excellent, even with the common use of immunomodulators corticosteroid dependence is seen in 45% of patients. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

9. 54 High Frequency of Non-Classical Endoscopic Findings in Children and Adolescents Diagnosed With UlcerativE.ColiTis. The Protect Study.

Author

Rosh, Joel R., Wang, Zhu, Mack, David R., Boyle, Brendan M., Griffiths, Anne M., Leleiko, Neal S., Sauer, Cary G., Keljo, David J., Markowitz, James, Baker, Susan S., Baldassano, Robert N., Patel, Ashish S., Pfefferkorn, Marian D., Otley, Anthony, Heyman, Mel, Noe, Joshua D., Oliva-Hemker, Maria, Rufo, Paul A., Strople, Jennifer A., and Ziring, David

Published
2017
Full Text
View/download PDF

10. 1090 - Predicting Non-Response to Intravenous Corticosteroid Induction Therapy in Children Newly Diagnosed with Severely Active Ulcerative Colitis: The Protect Study.

Author

Hyams, Jeffrey S., Davis, Sonia, Mack, David R., Boyle, Brendan M., Griffiths, Anne M., Leleiko, Neal S., Sauer, Cary G., Keljo, David J., Markowitz, James, Baker, Susan S., Rosh, Joel R., Baldassano, Robert N., Patel, Ashish S., Pfefferkorn, Marian D., Otley, Anthony, Heyman, Mel, Noe, Joshua D., Oliva-Hemker, Maria, Rufo, Paul A., and Gotman, Nathan

Published
2017
Full Text
View/download PDF

11. Tu1745 - Greater Contribution of HLA to Risk for Pediatric-Onset Ulcerative Colitis Can be Narrowed to 3 Independent Classic HLA Variants and Corresponding Amino Acid Changes.

Author

Prince, Jarod, Venkateswaran, Suresh, Cutler, David J., Okou, David, Chopra, Pankaj, Davis, Sonia, Baker, Susan S., Strople, Jennifer A., Hommel, Kevin A., Evans, Jonathan S., Sauer, Cary G., Markowitz, James, Rufo, Paul A., Pfefferkorn, Marian D., Ziring, David, Oliva-Hemker, Maria, Sudel, Boris, Kappelman, Michael, Rosh, Joel R., and Otley, Anthony

Published
2017
Full Text
View/download PDF

12. Tu1743 - Is Mesalamine Monotherapy Equally Effective in Inducing Remission in Mild Versus Moderate Pediatric Ulcerative Colitis at Diagnosis?

Author

Townsend, Peter, Davis, Sonia, Mack, David R., Boyle, Brendan M., Griffiths, Anne M., Leleiko, Neal S., Sauer, Cary G., Keljo, David J., Markowitz, James, Baker, Susan S., Rosh, Joel R., Baldassano, Robert N., Patel, Ashish S., Pfefferkorn, Marian D., Otley, Anthony, Heyman, Mel, Noe, Joshua D., Oliva-Hemker, Maria, Rufo, Paul A., and Strople, Jennifer A.

Published
2017
Full Text
View/download PDF

13. Tu1752 - Predicting Response to Mesalamine Induction Therapy in Children Newly Diagnosed with Mild-to-Moderate Ulcerative Colitis: The Protect Study.

Author

Denson, Lee A., Davis, Sonia, Mack, David R., Boyle, Brendan M., Griffiths, Anne M., Leleiko, Neal S., Sauer, Cary G., Keljo, David J., Markowitz, James, Baker, Susan S., Rosh, Joel R., Baldassano, Robert N., Patel, Ashish S., Pfefferkorn, Marian D., Otley, Anthony, Heyman, Melvin B., Noe, Joshua D., Oliva-Hemker, Maria, Rufo, Paul A., and Dubinsky, Marla

Published
2017
Full Text
View/download PDF

14. 874g - Microbial Dysbiosis Associated with Disease Severity in Treatment Naive Pediatric Patients with New-Onset Ulcerative Colitis.

Author

Schirmer, Melanie, Vlamakis, Hera, Denson, Lee A., Davis, Sonia, Rufo, Paul A., Baker, Susan S., Strople, Jennifer A., Sauer, Cary G., Markowitz, James, Pfefferkorn, Marian D., Ziring, David, Oliva-Hemker, Maria, Sudel, Boris, Rosh, Joel R., Otley, Anthony, Benkov, Keith J., Boyle, Brendan M., Mack, David R., Baldassano, Robert N., and Keljo, David J.

Published
2017
Full Text
View/download PDF

15. Tu1740 - Can we Simplify the Pediatric Ulcerative Colitis Index to the Point of Patient-Reported Outcomes Only?

Author

Grossi, Victoria, Wang, Zhu, Griffiths, Anne M., Mack, David R., Boyle, Brendan M., Leleiko, Neal S., Sauer, Cary G., Rosh, Joel R., Keljo, David J., Markowitz, James, Baker, Susan S., Baldassano, Robert N., Patel, Ashish S., Pfefferkorn, Marian D., Otley, Anthony, Heyman, Mel, Noe, Joshua D., Oliva-Hemker, Maria, Rufo, Paul A., and Kugathasan, Subra

Published
2017
Full Text
View/download PDF

16. 1088 - Suboptimal Early Outcomes following Standardized Induction Therapy in Children Newly Diagnosed with Ulcerative Colitis: The Protect Study.

Author

Hyams, Jeffrey S., Davis, Sonia, Mack, David R., Boyle, Brendan M., Griffiths, Anne M., Leleiko, Neal S., Sauer, Cary G., Keljo, David J., Markowitz, James, Baker, Susan S., Rosh, Joel R., Baldassano, Robert N., Patel, Ashish S., Pfefferkorn, Marian D., Otley, Anthony, Heyman, Mel, Noe, Joshua D., Oliva-Hemker, Maria, Rufo, Paul A., and Strople, Jennifer A.

Published
2017
Full Text
View/download PDF

17. Tu1753 - Predicting Response to Oral Corticosteroid Induction Therapy in Children Newly Diagnosed with Moderately Active Ulcerative Colitis: The Protect Study.

Author

Denson, Lee A., Davis, Sonia, Mack, David R., Boyle, Brendan M., Griffiths, Anne M., Leleiko, Neal S., Sauer, Cary G., Keljo, David J., Markowitz, James, Baker, Susan S., Rosh, Joel R., Baldassano, Robert N., Patel, Ashish S., Pfefferkorn, Marian D., Otley, Anthony, Heyman, Melvin B., Noe, Joshua D., Oliva-Hemker, Maria, Rufo, Paul A., and Dubinsky, Marla

Published
2017
Full Text
View/download PDF

18. 21 Surgery in Pediatric Crohn's Disease, 2002-2014.

Author

Kerur, Basavaraj, Machan, Jason T., Cerezo, Carolina, Markowitz, James, Mack, David R., Griffiths, Anne M., Otley, Anthony R., Pfefferkorn, Marian D., Rosh, Joel R., Keljo, David J., Crandall, Wallace V., Rick, James, Noe, Joshua, Oliva-Hemker, Maria, Kay, Marsha H., Saeed, Shehzad A., Grossman, Andrew B., Sudel, Boris, Kappelman, Michael, and Schaefer, Marc

Published
2016
Full Text
View/download PDF

19. 634 Serologic Reactivity Reflects Clinical and Genetic Expression of Ulcerative Colitis in Children. The Protect Study.

Author

Hyams, Jeffrey S., Dubinsky, Marla, Davis, Sonia, Walters, Thomas D., Mack, David R., Boyle, Brendan, Griffiths, Anne M., Leleiko, Neal S., Sauer, Cary, Keljo, David J., Markowitz, James, Baker, Susan S., Rosh, Joel R., Baldassano, Robert N., Oliva-Hemker, Maria, Pfefferkorn, Marian D., Otley, Anthony R., Heyman, Mel, Noe, Joshua, and Patel, Ashish S.

Published
2016
Full Text
View/download PDF

20. Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort.

Author

Oliva-Hemker, Maria, Hutfless, Susan, Al Kazzi, Elie S., Lerer, Trudy, Mack, David, LeLeiko, Neal, Griffiths, Anne, Cabrera, Jose, Otley, Anthony, Rick, James, Bousvaros, Athos, Rosh, Joel, Grossman, Andrew, Saeed, Shehzad, Kay, Marsha, Carvalho, Ryan, Keljo, David, Pfefferkorn, Marian, Jr.Faubion, William, and Kappelman, Michael

Abstract

Objective To evaluate the presentation, therapeutic management, and long-term outcome of children with very early-onset (VEO) (≤5 years of age) inflammatory bowel disease (IBD). Study design Data were obtained from an inception cohort of 1928 children with IBD enrolled in a prospective observational registry at multiple centers in North America. Results One hundred twelve children were ≤5 years of age with no child enrolled at <1 year of age. Of those, 42.9% had Crohn's disease (CD), 46.4% ulcerative colitis (UC), and 10.7% had IBD-unclassified. Among the children with CD, children 1-5 years of age had more isolated colonic disease (39.6%) compared with 6- to 10-year-olds (25.3%, P = .04), and 11- to 16-year-olds (22.3%, P < .01). The change from a presenting colon-only phenotype to ileocolonic began at 6-10 years. Children 1-5 years of age with CD had milder disease activity (45.8%) at diagnosis compared with the oldest group (28%, P = .01). Five years postdiagnosis, there was no difference in disease activity among the 3 groups. However, compared with the oldest group, a greater proportion of 1- to 5-year-olds with CD were receiving corticosteroids ( P < .01) and methotrexate ( P < .01), and a greater proportion of 1- to 5-year-olds with UC were receiving mesalamine ( P < .0001) and thiopurine immunomodulators ( P < .0002). Conclusions Children with VEO-CD are more likely to have mild disease at diagnosis and present with a colonic phenotype with change to an ileocolonic phenotype noted at 6-10 years of age. Five years after diagnosis, children with VEO-CD and VEO-UC are more likely to have been administered corticosteroids and immunomodulators despite similar disease activity in all age groups. This may suggest development of a more aggressive disease phenotype over time. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

22. Su1195 Simple Blood Testing Defines Severe New Onset Ulcerative Colitis in Children: The PROTECT Study.

Author

Mack, David R., Saul, Bradley, Davis, Sonia, Marquis, Alison, Boyle, Brendan, Griffiths, Anne M., Sauer, Cary, Markowitz, James, Leleiko, Neal S., Rosh, Joel R., Keljo, David J., Baker, Susan S., Pfefferkorn, Marian D., Heyman, Melvin B., Patel, Ashish S., Oliva-Hemker, Maria, Baldassano, Robert, Noe, Joshua D., Rufo, Paul A., and Otley, Anthony R.

Published
2015
Full Text
View/download PDF

23. Sa1999 Patient Related Outcomes and Disease Activity Indices in New Onset Pediatric Ulcerative Colitis: The PROTECT Study.

Author

Walters, Thomas D., Mack, David R., Boyle, Brendan, Griffiths, Anne M., Sauer, Cary, Leleiko, Neal S., Markowitz, James, Keljo, David J., Rosh, Joel R., Baker, Susan S., Heyman, Melvin B., Patel, Ashish S., Pfefferkorn, Marian D., Baldassano, Robert, Noe, Joshua D., Oliva-Hemker, Maria, Otley, Anthony R., Rufo, Paul A., Benkov, Keith J., and Ziring, David

Published
2015
Full Text
View/download PDF

24. Su1234 Histologic Correlates of Clinical and Endoscopic Severity in Newly Diagnosed Pediatric Ulcerative Colitis: The PROTECT Study.

Author

Boyle, Brendan, Collins, Margaret H., Wang, Zhu, Mack, David R., Griffiths, Anne M., Sauer, Cary, Markowitz, James, Leleiko, Neal S., Keljo, David J., Rosh, Joel R., Baker, Susan S., Pfefferkorn, Marian D., Heyman, Melvin B., Patel, Ashish S., Oliva-Hemker, Maria, Baldassano, Robert, Noe, Joshua D., Rufo, Paul A., Otley, Anthony R., and Benkov, Keith J.

Published
2015
Full Text
View/download PDF

27. Sa1884 Infliximab Versus Immunomodulator as First Maintenance Therapy in Children With Crohn Disease.

Author

Markowitz, James, Evans, Jonathan, Pfefferkorn, Marian D., Griffiths, Anne M., Keljo, David J., Mack, David R., Carvalho, Ryan, Leleiko, Neal S., Otley, Anthony R., Rosh, Joel R., Stephens, Michael C., Saeed, Shehzad A., Ashai-Khan, Farhat N., Bousvaros, Athos, Kay, Marsha H., Oliva-Hemker, Maria, Grossman, Andrew B., Sudel, Boris, Kappelman, Michael, and Dimmitt, Reed A.

Published
2012
Full Text
View/download PDF

28. 142 Prospective Multicenter Pediatric Cohort Study: Patients With Liver Enzyme Elevations in the First 3 Months After Diagnosis of Inflammatory Bowel Disease are at Increased Risk of Chronic Liver Disease.

Author

Goyal, Alka, Hyams, Jeffrey S., Lerer, Trudy, Leleiko, Neal S., Otley, Anthony R., Griffiths, Anne M., Evans, Jonathan, Rosh, Joel R., Stephens, Michael C., Bousvaros, Athos, Oliva-Hemker, Maria, Mack, David R., Ashai-Khan, Farhat N., Pfefferkorn, Marian D., Carvalho, Ryan, Grossman, Andrew B., Hitch, Meredith C., Sudel, Boris, Kappelman, Michael, and Saeed, Shehzad A.

Published
2012
Full Text
View/download PDF

29. 141 Assessment of Durability of Infliximab Maintenance Therapy in Children With Crohn's Disease.

Author

Pfefferkorn, Marian D., Lerer, Trudy, Mack, David R., Evans, Jonathan, Keljo, David J., Kay, Marsha H., Rosh, Joel R., Otley, Anthony R., Stephens, Michael C., Oliva-Hemker, Maria, Leleiko, Neal S., Bousvaros, Athos, Carvalho, Ryan, Ashai-Khan, Farhat N., Grossman, Andrew B., Saeed, Shehzad A., Hitch, Meredith C., Kappelman, Michael, Sudel, Boris, and Faubion, William A.

Published
2012
Full Text
View/download PDF

30. 140 Anti-Microbial Serology Patterns in 824 Children With Newly Diagnosed Crohn's Disease: Association With GM-CSF Auto-Antibodies and Specific Clinical Phenotypes.

Author

Walters, Thomas D., Dubinsky, Marla, Griffiths, Anne M., Baldassano, Robert, Hyams, Jeffrey S., Stephens, Michael C., Markowitz, James, Crandall, Wallace, Heyman, Melvin B., Kellermayer, Richard, Mack, David R., Oliva-Hemker, Maria, Patel, Ashish S., Kirschner, Barbara S., Moulton, Dedrick E., Cohen, Stanley A., Aronow, Bruce, Denson, Lee, and Kugathasan, Subra

Published
2012
Full Text
View/download PDF

31. 139 Long-Term Outcomes After Institution of Adalimumab Therapy in Pediatric Crohn Disease.

Author

Rosh, Joel R., Lerer, Trudy, Stephens, Michael C., Carvalho, Ryan, Pfefferkorn, Marian D., Evans, Jonathan, Griffiths, Anne M., Otley, Anthony R., Bousvaros, Athos, Grossman, Andrew B., Ashai-Khan, Farhat N., Leleiko, Neal S., Keljo, David J., Kay, Marsha H., Hitch, Meredith C., Saeed, Shehzad A., Oliva-Hemker, Maria, Mack, David R., Markowitz, James, and Hyams, Jeffrey S.

Published
2012
Full Text
View/download PDF

32. Changing Trends in Pharmacologic Therapy of Pediatric Crohn's Disease.

Author

Ofei, Sylvia, Carvalho, Ryan, Hyams, Jeffrey S., Lerer, Trudy, Schaefer, Marc, Machan, Jason T., Langton, Christine R., Mack, David R., Evans, Jonathan, Pfefferkorn, Marian D., Griffiths, Anne M., Otley, Anthony R., Bousvaros, Athos, Keljo, David J., Kay, Marsha H., Oliva-Hemker, Maria, Kappelman, Michael, Saeed, Shehzad A., LeLeiko, Neal S., and Stephens, Michael C.

Published
2011
Full Text
View/download PDF

33. Outcomes Following Aminosalicylate Therapy in Children Newly Diagnosed With Ulcerative Colitis: A Prospective Multi-Center Registry Experience.

Author

Zeisler, Bella, Lerer, Trudy, Markowitz, James, Mack, David R., Griffiths, Anne M., Bousvaros, Athos, Keljo, David J., Rosh, Joel R., Evans, Jonathan, Kappelman, Michael, Otley, Anthony R., Kay, Marsha H., Grossman, Andrew B., Samson, Charles M., Saeed, Shehzad A., Carvalho, Ryan, Oliva-Hemker, Maria, Faubion, William A., Sudel, Boris, and Pfefferkorn, Marian D.

Published
2011
Full Text
View/download PDF

34. Post-Intestinal Resection Management of Pediatric Crohn's Disease.

Author

Schaefer, Marc, Langton, Christine R., Markowitz, James, Mack, David R., Evans, Jonathan, Pfefferkorn, Marian D., Griffiths, Anne M., Otley, Anthony R., Bousvaros, Athos, Rosh, Joel R., Keljo, David J., Carvalho, Ryan, Kay, Marsha H., Oliva-Hemker, Maria, Kappelman, Michael, Ashai-Khan, Farhat N., Stephens, Michael C., Samson, Charles M., Grossman, Andrew B., and Dimmitt, Reed A.

Published
2011
Full Text
View/download PDF

37. S2005 Clinical Effect and Changing Patterns of use of Methotrexate in the Treatment of Pediatric Crohn's Disease: A Multi-Center Experience.

Author

Rosh, Joel R., Mohamed, Alliya, Dougherty, Kelly, Lerer, Trudy, Keljo, David J., Mack, David R., Griffiths, Anne M., Crandall, Wallace, Bousvaros, Athos, Kay, Marsha H., Grossman, Andrew B., Pfefferkorn, Marian D., Michail, Sonia, Stephens, Michael, Samson, Charles M., LeLeiko, Neal S., Oliva-Hemker, Maria, Saeed, Shehzad, Kappelman, Michael, and Otley, Anthony R.

Published
2010
Full Text
View/download PDF

38. S1189 Upper Gastrointestinal Involvement in Pediatric Crohn's Disease: Experience of a Large Multicenter Inception Cohort.

Author

Mack, David R., Markowitz, James, Lerer, Trudy, Griffiths, Anne M., Evans, Jonathan S., Otley, Anthony R., Bousvaros, Athos, Pfefferkorn, Marian D., Rosh, Joel R., Crandall, Wallace, Michail, Sonia, Oliva-Hemker, Maria, Kay, Marsha H., Samson, Charles M., Keljo, David J., Kappelman, Michael, Stephens, Michael, Grossman, Andrew B., Saeed, Shehzad, and LeLeiko, Neal S.

Published
2010
Full Text
View/download PDF

39. 506 Outcome Following Thiopurine use in Children With Ulcerative Colitis: A Prospective Multicenter Study.

Author

Hyams, Jeffrey S., Lerer, Trudy, Mack, David R., Bousvaros, Athos, Griffiths, Anne M., Rosh, Joel R., Otley, Anthony R., Evans, Jonathan S., Stephens, Michael, Kay, Marsha H., Keljo, David J., LeLeiko, Neal S., Saeed, Shehzad, Crandall, Wallace, Michail, Sonia, Kappelman, Michael, Samson, Charles M., Sudel, Boris, Oliva-Hemker, Maria, and Pfefferkorn, Marian D.

Published
2010
Full Text
View/download PDF

40. W1198 Medication Use and Disease Characteristics in Early-Onset and Later-Onset Pediatric Inflammatory Bowel Disease (IBD).

Author

Oliva-Hemker, Maria, Hutfless, Susan, Hyams, Jeffrey S., Langton, Christine R., Lerer, Trudy, Bousvaros, Athos, Carvalho, Ryan S., Crandall, Wallace, Evans, Jonathan, Griffiths, Anne M., Kay, Marsha H., Keljo, David J., Kugathasan, Subra, LeLeiko, Neal S., Mack, David R., Mamula, Petar, Otley, Anthony R., Pfefferkorn, Marian D., Rosh, Joel R., and Markowitz, James

Published
2009
Full Text
View/download PDF

42. W1189 Indeterminate Colitis (IC) in Children: A Two-Year Follow-Up.

Author

Lora, Melissa, Pfefferkorn, Marian D., Langton, Christine R., Markowitz, James, Evans, Jonathan, Rosh, Joel R., Kay, Marsha H., Crandall, Wallace, Keljo, David J., Otley, Anthony R., Kugathasan, Subra, Carvalho, Ryan S., Oliva-Hemker, Maria, Bousvaros, Athos, Leleiko, Neal S., Mack, David R., Griffiths, Anne M., and Hyams, Jeffrey S.

Published
2009
Full Text
View/download PDF

43. W1188 Growth in Pediatric Patients with IBD Treated with Infliximab or 6-Mercaptopurine/Azathioprine.

Author

Keljo, David J., Markowitz, James, Langton, Christine R., Lerer, Trudy, Bousvaros, Athos, Carvalho, Ryan S., Crandall, Wallace, Evans, Jonathan, Griffiths, Anne M., Kay, Marsha H., Kugathasan, Subra, LeLeiko, Neal S., Mack, David R., Oliva-Hemker, Maria, Otley, Anthony R., Pfefferkorn, Marian D., Rosh, Joel R., Tomer, Gitit, and Hyams, Jeffrey S.

Published
2009
Full Text
View/download PDF

45. 1108 A Prediction Tool to Help Children with Crohn's Disease and Their Parents Understand Individualized Risks of Disease Complications and Response to Therapy.

Author

Siegel, Corey A., Siegel, Lori S., Hyams, Jeffrey S., Kugathasan, Subra, Markowitz, James, Rosh, Joel R., Leleiko, Neal, Mack, David R., Crandall, Wallace, Evans, Jonathan, Keljo, David J., Otley, Anthony R., Oliva-Hemker, Maria, Langton, Christine R., Wrobel, Iwona T., Wahbeh, Ghassan, Quiros, Antonio, Silber, Gary, Bahar, Ron J., and Sands, Bruce E.

Published
2009
Full Text
View/download PDF

49. 924 Long-Term Outcome Following Infliximab Therapy in Pediatric Patients with Crohn Disease: Results from a Multicenter Study.

Author

Hyams, Jeffrey S., Lerer, Trudy, Pfefferkorn, Marian D., Kugathasan, Subra, Evans, Jonathan, Otley, Anthony R., Griffiths, Anne M., Carvalho, Ryan S., Mack, David R., Bousvaros, Athos, Rosh, Joel R., Mamula, Petar, Moyer, M. Susan, Kay, Marsha H., Crandall, Wallace, Oliva-Hemker, Maria, Keljo, David, LeLeiko, Neal S., and Markowitz, James

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results